| ID | 1616 | |
| PMID | 25041740 | |
| Year | 2014 | |
| Sequence | LLGDFFRKSKEKIGK EFKRIVQRIKDFLRN LVPRTES | |
| Name | LL-37 | |
| Length | 37 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Linear | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | Synthetic | |
| Nature of Peptide/Cargo | Not mentioned | |
| Mechanism | Not well understood | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | Statistical analysis was done in order to measure the efficacy of LL-37 as a drug. | |
| Enhancer | None | |
| Properties of enhancer | Not applicable | |
| Concentration | 3.2 mg/ml | |
| Incubation time | 4 weeks | |
| Tissue permeability (value with units) | The ulcers upto 89%. | |
| Tissue Sample | Human skin | |
| Ex vivo/In vivo/In vitro | in vitro | |
| STRUCTURE |
| |
| SMILES | N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N [C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C (=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H] (C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H] (C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H] (C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N [C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O) N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C (=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H] (C(=O)N[C@H](C(=O)N[C@H](C=O)CO)CCC(=O)O) [C@H](O)C)CCCNC(=N)N)CCC)C(C)C)CC (C)C)CC(=O)N)CCCNC(=N)N)CC(C)C)Cc1 ccccc1)CC(=O)O)CCCCN)[C@H](CC)C)CCCNC(=N)N) CCC(=O)N)C(C)C)[C@H](CC)C)CCCNC(=N)N)CCCCN) Cc1ccccc1)CCC(=O)O)CCCCN)[C@H](CC)C)CCCCN) CCC(=O)O)CCCCN)CO)CCCCN)CCCNC(=N)N)Cc1ccccc1) Cc1ccccc1)CC(=O)O)CC(C)C)CC(C)C | |